Matthew Stanton - Generation Bio Chief Officer
| GBIO Stock | USD 1.40 0.03 2.19% |
Insider
Matthew Stanton is Chief Officer of Generation Bio Co
| Age | 51 |
| Address | 301 Binney Street, Cambridge, MA, United States, 02142 |
| Phone | 617 655 7500 |
| Web | https://generationbio.com |
Matthew Stanton Latest Insider Activity
Tracking and analyzing the buying and selling activities of Matthew Stanton against Generation Bio stock is an integral part of due diligence when investing in Generation Bio. Matthew Stanton insider activity provides valuable insight into whether Generation Bio is net buyers or sellers over its current business cycle. Note, Generation Bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Generation Bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Matthew Stanton over three months ago Disposition of 7437 shares by Matthew Stanton of Generation Bio subject to Rule 16b-3 | ||
Matthew Stanton over three months ago Disposition of 1674 shares by Matthew Stanton of Generation Bio subject to Rule 16b-3 | ||
Matthew Stanton over six months ago Exercise or conversion by Matthew Stanton of 7437 shares of Generation BioCo subject to Rule 16b-3 | ||
Matthew Stanton over a year ago Exercise or conversion by Matthew Stanton of 7437 shares of Generation BioCo subject to Rule 16b-3 |
Generation Bio Management Efficiency
The company has return on total asset (ROA) of (0.1929) % which means that it has lost $0.1929 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.865) %, meaning that it created substantial loss on money invested by shareholders. Generation Bio's management efficiency ratios could be used to measure how well Generation Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.35. In addition to that, Return On Capital Employed is likely to drop to -0.43. At this time, Generation Bio's Non Currrent Assets Other are very stable compared to the past year. As of the 26th of November 2024, Asset Turnover is likely to grow to 0.01, while Total Assets are likely to drop about 302.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Eliem Therapeutics | 63 | |
| Bradley JD | Lumos Pharma | 45 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| Hing Wong | HCW Biologics | 70 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| BBA CPA | Lumos Pharma | 57 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Jeff York | Seres Therapeutics | N/A | |
| Carl Langren | Lumos Pharma | 69 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Peter Rhode | HCW Biologics | 66 | |
| Lori CPA | Lumos Pharma | 40 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
Management Performance
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.19 |
Generation Bio Leadership Team
Elected by the shareholders, the Generation Bio's board of directors comprises two types of representatives: Generation Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Generation. The board's role is to monitor Generation Bio's management team and ensure that shareholders' interests are well served. Generation Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Generation Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Kotin, CoFounder Advisor | ||
| Sara Besten, Chief Officer | ||
| Tracy Zimmermann, Chief Officer | ||
| Phillip Samayoa, Chief Officer | ||
| Jasmin Tower, Chief Officer | ||
| MBA MD, Chief Officer | ||
| Cameron MD, CEO and President | ||
| MD MBA, Chief Officer | ||
| Esq JD, Chief Officer | ||
| Yalonda JD, Chief Secretary | ||
| Mark Angelino, CoFounder | ||
| Matthew Stanton, Chief Officer | ||
| MS MBA, Chief Officer |
Generation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Generation Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (2.21) % | ||||
| Current Valuation | 515.17 K | ||||
| Shares Outstanding | 66.79 M | ||||
| Shares Owned By Insiders | 14.51 % | ||||
| Shares Owned By Institutions | 83.88 % | ||||
| Number Of Shares Shorted | 1.66 M | ||||
| Price To Book | 0.88 X | ||||
| Price To Sales | 5.03 X |
Pair Trading with Generation Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Generation Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Generation Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Generation Stock
| 0.64 | A | Agilent Technologies | PairCorr |
| 0.85 | ME | 23Andme Holding | PairCorr |
| 0.71 | VALN | Valneva SE ADR | PairCorr |
| 0.73 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Generation Stock
| 0.57 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.54 | RNXT | RenovoRx | PairCorr |
| 0.35 | KZR | Kezar Life Sciences | PairCorr |
| 0.33 | KEP | Korea Electric Power | PairCorr |
The ability to find closely correlated positions to Generation Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Generation Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Generation Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Generation Bio Co to buy it.
The correlation of Generation Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Generation Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Generation Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Generation Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Generation Bio Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Generation Bio. If investors know Generation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Generation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Revenue Per Share 0.28 | Quarterly Revenue Growth 2.52 | Return On Assets (0.19) | Return On Equity (0.86) |
The market value of Generation Bio is measured differently than its book value, which is the value of Generation that is recorded on the company's balance sheet. Investors also form their own opinion of Generation Bio's value that differs from its market value or its book value, called intrinsic value, which is Generation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Generation Bio's market value can be influenced by many factors that don't directly affect Generation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Generation Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Generation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Generation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.